SIGY
Sigyn Therapeutics, Inc.
Price Chart
Latest Quote
$0.04
+0.00 (+0.00%)
Current Price
| Previous Close | $0.04 |
| Open | $0.04 |
| Day High | $0.04 |
| Day Low | $0.04 |
| Volume | 9,900 |
Stock Information
| Shares Outstanding | 1.61M |
| Total Debt | $2.81M |
| Cash Equivalents | $86K |
| Net Income | $-3.22M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $63K |
| EPS (TTM) | $-1.93 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.79M |
| Income | $-3.22M |
| Book/sh | $-3.69 |
| Cash/sh | $0.05 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 0.02 |
| Current Ratio | 0.02 |
Returns & Margins
| ROA | -417.42% |
Ownership
| Insider Ownership | 70.67% |
| Institutional Ownership | 5.27% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -0.01 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.04 |
| SMA50 | $0.04 |
| SMA200 | $1.25 |
| RSI | 50.00 |
| ATR | 0.0026 |
| Shares Float | 889K |
| Volatility | -0.07 |
| Rel Volume | 1.11 |
Performance History
| Week | -2.50% |
| Month | +14.71% |
| Quarter | -51.25% |
| 6 Months | -97.86% |
| YTD | -97.72% |
| Year | -98.58% |
| 3 Years | -98.93% |
| 5 Years | -99.90% |
| 10 Years | -99.93% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-15 | $0.04 | 20,800 |
| 2026-06-12 | $0.04 | 0 |
| 2026-06-11 | $0.04 | 10,000 |
| 2026-06-10 | $0.04 | 0 |
| 2026-06-09 | $0.04 | 0 |
| 2026-06-08 | $0.04 | 3,000 |
| 2026-06-05 | $0.04 | 200 |
| 2026-06-04 | $0.04 | 900 |
| 2026-06-03 | $0.04 | 41,100 |
| 2026-06-02 | $0.04 | 26,000 |
| 2026-06-01 | $0.04 | 30,000 |
| 2026-05-29 | $0.04 | 30,000 |
| 2026-05-28 | $0.04 | 0 |
| 2026-05-27 | $0.04 | 25,300 |
| 2026-05-26 | $0.04 | 0 |
| 2026-05-22 | $0.04 | 41,800 |
| 2026-05-21 | $0.04 | 74,100 |
| 2026-05-20 | $0.04 | 40,600 |
| 2026-05-19 | $0.04 | 100 |
| 2026-05-18 | $0.04 | 32,000 |
About Sigyn Therapeutics, Inc.
Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats. The company is also involved in the evaluation of Sigyn therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the performance of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on SIGY.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $859,915 | $2,043,584 | $782,552 | $460,355 |
| Total Expenses | $2,519,242 | $2,455,317 | $2,147,265 | $2,008,217 |
| Other Income Expense | $38,945 | $352,965 | - | $-536,047 |
| Net Non Operating Interest Income Expense | $-859,915 | $-2,043,584 | $-782,552 | $-460,355 |
| Interest Expense Non Operating | $859,915 | $2,043,584 | $782,552 | $460,355 |
| Operating Expense | $2,519,242 | $2,455,317 | $2,147,265 | $2,008,217 |
| Selling And Marketing Expense | $1,130 | $392 | $457 | $0 |
| General And Administrative Expense | $1,744,833 | $1,656,760 | $1,489,151 | $1,274,203 |
| Total Other Finance Cost | - | - | $135,812 | $61,283 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,340,212 | $-4,145,936 | $-2,929,817 | $-3,004,619 |
| Net Interest Income | $-859,915 | $-2,043,584 | $-782,552 | $-460,355 |
| Normalized Income | $-3,379,157 | $-4,498,901 | $-2,929,817 | $-2,468,572 |
| Net Income From Continuing And Discontinued Operation | $-3,340,212 | $-4,145,936 | $-2,929,817 | $-3,004,619 |
| Total Operating Income As Reported | $-2,519,242 | $-2,455,317 | $-2,147,265 | $-2,008,217 |
| Net Income Common Stockholders | $-3,340,212 | $-4,145,936 | $-2,929,817 | $-3,004,619 |
| Net Income | $-3,340,212 | $-4,145,936 | $-2,929,817 | $-3,004,619 |
| Net Income Including Noncontrolling Interests | $-3,340,212 | $-4,145,936 | $-2,929,817 | $-3,004,619 |
| Net Income Continuous Operations | $-3,340,212 | $-4,145,936 | $-2,929,817 | $-3,004,619 |
| Pretax Income | $-3,340,212 | $-4,145,936 | $-2,929,817 | $-3,004,619 |
| Operating Income | $-2,519,242 | $-2,455,317 | $-2,147,265 | $-2,008,217 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Special Income Charges | - | - | $0 | $-536,047 |
| Per Share | ||||
| Diluted EPS | $-2.51 | $-3.77 | $-3.13 | $-3.20 |
| Basic EPS | $-2.51 | $-3.77 | $-3.13 | $-3.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,513,631 | $-2,446,461 | $-2,136,811 | $-1,989,066 |
| Total Unusual Items | $38,945 | $352,965 | $0 | $-536,047 |
| Total Unusual Items Excluding Goodwill | $38,945 | $352,965 | $0 | $-536,047 |
| Reconciled Depreciation | $5,611 | $8,856 | $10,454 | $19,151 |
| EBITDA (Bullshit earnings) | $-2,474,686 | $-2,093,496 | $-2,136,811 | $-2,525,113 |
| EBIT | $-2,480,297 | $-2,102,352 | $-2,147,265 | $-2,544,264 |
| Diluted Average Shares | $1,332,449 | $1,100,372 | $934,915 | $909,914 |
| Basic Average Shares | $1,332,449 | $1,100,372 | $934,915 | $909,914 |
| Diluted NI Availto Com Stockholders | $-3,340,212 | $-4,145,936 | $-2,929,817 | $-3,004,619 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Security | $38,945 | $352,965 | - | - |
| Research And Development | $773,279 | $798,165 | $657,657 | $734,014 |
| Selling General And Administration | $1,745,963 | $1,657,152 | $1,489,608 | $1,274,203 |
| Other Gand A | $1,744,833 | $1,656,760 | $1,489,151 | $1,274,203 |
| Write Off | - | - | $0 | $536,047 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-4,457,624 | $-3,412,500 | $-1,905,340 | $-270,284 |
| Total Assets | $213,719 | $321,806 | $332,879 | $710,259 |
| Total Non Current Assets | $192,475 | $203,743 | $262,581 | $317,228 |
| Other Non Current Assets | $70,711 | $20,711 | $20,711 | $20,711 |
| Current Assets | $21,244 | $118,063 | $70,298 | $393,031 |
| Other Current Assets | $9,100 | $56,373 | $11,942 | $2,075 |
| Inventory | $0 | $50,000 | $50,000 | $50,000 |
| Cash Cash Equivalents And Short Term Investments | $12,144 | $11,690 | $8,356 | $340,956 |
| Cash And Cash Equivalents | $12,144 | $11,690 | $8,356 | $340,956 |
| Cash Financial | $12,144 | $11,690 | $8,356 | $340,956 |
| Goodwill And Other Intangible Assets | - | $0 | $2,100 | $5,700 |
| Other Intangible Assets | - | - | $2,100 | $5,700 |
| Receivables | - | - | - | $0 |
| Accounts Receivable | - | - | - | $0 |
| Debt | ||||
| Net Debt | $2,053,798 | $2,198,609 | $1,628,300 | $306,246 |
| Total Debt | $2,192,244 | $2,397,724 | $1,877,281 | $933,918 |
| Long Term Debt And Capital Lease Obligation | $56,356 | $126,302 | $187,425 | $240,625 |
| Current Debt And Capital Lease Obligation | $2,135,888 | $2,271,422 | $1,689,856 | $693,293 |
| Current Debt | $2,065,942 | $2,210,299 | $1,636,656 | $647,202 |
| Other Current Borrowings | $1,891,736 | $2,210,299 | $1,636,656 | $647,202 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,671,343 | $3,734,306 | $2,236,119 | $974,843 |
| Total Non Current Liabilities Net Minority Interest | $56,356 | $126,302 | $187,425 | $240,625 |
| Current Liabilities | $4,614,987 | $3,608,004 | $2,048,694 | $734,218 |
| Other Current Liabilities | $1,742 | $3,182 | $1,197 | $179 |
| Current Notes Payable | $174,206 | $0 | - | - |
| Payables And Accrued Expenses | $2,477,357 | $1,333,400 | $357,641 | $40,746 |
| Payables | $608,384 | $541,646 | $327,517 | $39,674 |
| Accounts Payable | $608,384 | $461,646 | $327,517 | $39,674 |
| Equity | ||||
| Common Stock Equity | $-4,457,624 | $-3,412,500 | $-1,903,240 | $-264,584 |
| Total Equity Gross Minority Interest | $-4,457,624 | $-3,412,500 | $-1,903,240 | $-264,584 |
| Stockholders Equity | $-4,457,624 | $-3,412,500 | $-1,903,240 | $-264,584 |
| Retained Earnings | $-14,681,724 | $-11,341,512 | $-7,195,576 | $-4,265,759 |
| Other | ||||
| Ordinary Shares Number | $1,605,377 | $1,288,415 | $956,595 | $932,395 |
| Share Issued | $1,605,377 | $1,288,415 | $956,595 | $932,395 |
| Tangible Book Value | $-4,457,624 | $-3,412,500 | $-1,905,340 | $-270,284 |
| Invested Capital | $-2,391,682 | $-1,202,201 | $-266,584 | $382,618 |
| Working Capital | $-4,593,743 | $-3,489,941 | $-1,978,396 | $-341,187 |
| Capital Lease Obligations | $126,302 | $187,425 | $240,625 | $286,716 |
| Total Capitalization | $-4,457,624 | $-3,412,500 | $-1,903,240 | $-264,584 |
| Additional Paid In Capital | $10,223,939 | $7,928,883 | $5,292,240 | $3,997,445 |
| Capital Stock | $161 | $129 | $96 | $3,730 |
| Common Stock | $161 | $129 | $96 | $3,730 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $56,356 | $126,302 | $187,425 | $240,625 |
| Current Capital Lease Obligation | $69,946 | $61,123 | $53,200 | $46,091 |
| Current Accrued Expenses | $1,868,973 | $791,754 | $30,124 | $1,072 |
| Dueto Related Parties Current | $0 | $80,000 | $0 | - |
| Net PPE | $121,764 | $183,032 | $239,770 | $290,817 |
| Accumulated Depreciation | $-22,513 | $-16,902 | $-10,146 | $-3,292 |
| Gross PPE | $144,277 | $199,934 | $249,916 | $294,109 |
| Other Properties | $112,079 | $167,736 | $217,718 | $262,771 |
| Machinery Furniture Equipment | $32,198 | $32,198 | $32,198 | $31,338 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-872,436 | $-1,383,210 | $-1,831,102 | $-1,803,446 |
| Operating Activities | ||||
| Operating Cash Flow | $-872,436 | $-1,383,210 | $-1,830,242 | $-1,774,182 |
| Cash Flow From Continuing Operating Activities | $-872,436 | $-1,383,210 | $-1,830,242 | $-1,774,182 |
| Operating Gains Losses | $-38,945 | $-352,965 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $-860 | $-29,264 |
| Cash Flow From Continuing Investing Activities | - | $0 | $-860 | $-29,264 |
| Capital Expenditure | - | - | $-860 | $-29,264 |
| Financing Activities | ||||
| Financing Cash Flow | $872,890 | $1,386,544 | $1,498,502 | $2,060,000 |
| Cash Flow From Continuing Financing Activities | $872,890 | $1,386,544 | $1,498,502 | $2,060,000 |
| Net Other Financing Charges | $-80,000 | $74,544 | $-68,498 | - |
| Issuance Of Capital Stock | - | - | $0 | $1,865,000 |
| Net Common Stock Issuance | - | - | $0 | $1,865,000 |
| Common Stock Issuance | - | - | $0 | $1,865,000 |
| Other | ||||
| Issuance Of Debt | $952,890 | $1,312,000 | $1,567,000 | $250,000 |
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $12,144 | $11,690 | $8,356 | $340,956 |
| Beginning Cash Position | $11,690 | $8,356 | $340,956 | $84,402 |
| Changes In Cash | $454 | $3,334 | $-332,600 | $256,554 |
| Net Issuance Payments Of Debt | $952,890 | $1,312,000 | $1,567,000 | $195,000 |
| Net Short Term Debt Issuance | $952,890 | $1,312,000 | $1,567,000 | $195,000 |
| Short Term Debt Issuance | $952,890 | $1,312,000 | $1,567,000 | $250,000 |
| Change In Working Capital | $1,264,324 | $850,095 | $307,007 | $-34,149 |
| Change In Other Current Liabilities | $-6,906 | $-1,233 | $-21 | $23,603 |
| Change In Other Current Assets | $47,273 | $-44,431 | $-9,867 | $-22,786 |
| Change In Payables And Accrued Expense | $1,223,957 | $895,759 | $316,895 | $-34,966 |
| Change In Accrued Expense | $1,077,219 | $699,130 | $29,052 | $-58,635 |
| Change In Payable | $146,738 | $196,629 | $287,843 | $23,669 |
| Change In Account Payable | $146,738 | $196,629 | $287,843 | $23,669 |
| Other Non Cash Items | $1,086,786 | $2,041,182 | $782,114 | $709,388 |
| Stock Based Compensation | $150,000 | $215,558 | $0 | - |
| Depreciation Amortization Depletion | $5,611 | $8,856 | $10,454 | $19,151 |
| Depreciation And Amortization | $5,611 | $8,856 | $10,454 | $19,151 |
| Amortization Cash Flow | $0 | $2,100 | $3,600 | $16,205 |
| Amortization Of Intangibles | $0 | $2,100 | $3,600 | $16,205 |
| Depreciation | $5,611 | $6,756 | $6,854 | $2,946 |
| Gain Loss On Investment Securities | $-38,945 | $-352,965 | - | - |
| Net Income From Continuing Operations | $-3,340,212 | $-4,145,936 | $-2,929,817 | $-3,004,619 |
| Net PPE Purchase And Sale | - | $0 | $-860 | $-29,264 |
| Purchase Of PPE | - | $0 | $-860 | $-29,264 |
| Repayment Of Debt | - | - | $0 | $-55,000 |
| Short Term Debt Payments | - | - | $0 | $-55,000 |
| Asset Impairment Charge | - | - | $0 | $536,047 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
Fetched: 2026-02-02